CYTXClinical•globenewswire•
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Positive (70)
Summary
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire